MHRA consults on bespoke regulation of ‘point of care’ products
Personalised treatments manufactured at the point of care in the UK, including cell and gene therapies, would be subject to a bespoke new regulatory framework under plans being developed by the Medicines and Healthcare products Regulatory Agency (MHRA).
